Originally published as JCO Early Release 10.1200/JCO.2008.20.7977 on July 6 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hess, G. Articles by Coiffier, B. Search for Related Content PubMed PubMed Citation Articles by Hess, G. Articles by Coiffier, B. Social Bookmarking                            What's this?

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

From the Johannes Gutenberg-University, Mainz, Germany; Hôpital de Hautepierre, Strasbourg; Hôpital Saint-Louis, Paris; Hôpital Lyon Sud, Pierre Bénite, France; The University of Texas M. D. Anderson Cancer Center, Houston, TX; University Hospital Gasthuisberg, Leuven; University Hospital Gent, Gent, Belgium; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital, Uppsala, Sweden; and Wyeth Research, Cambridge, MA.

Corresponding author: Georg Hess, MD, Department of Hematology/Oncology, Johannes Gutenberg-University, Langenbeckstr 1, Mainz, DE 55101; e-mail: g.hess{at}3-med.klinik.uni-mainz.de.

Purpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or refractory disease.

Patients and Methods In this multicenter, open-label, phase III study, 162 patients with relapsed or refractory MCL were randomly assigned (1:1:1) to receive one of two temsirolimus regimens: 175 mg weekly for 3 weeks followed by either 75 mg (175/75-mg) or 25 mg (175/25-mg) weekly, or investigator's choice therapy from prospectively approved options. The primary end point was progression-free survival (PFS) by independent assessment.

Results Median PFS was 4.8, 3.4, and 1.9 months for the temsirolimus 175/75-mg, 175/25-mg, and investigator's choice groups, respectively. Patients treated with temsirolimus 175/75-mg had significantly longer PFS than those treated with investigator's choice therapy (P = .0009; hazard ratio = 0.44); those treated with temsirolimus 175/25-mg showed a trend toward longer PFS (P = .0618; hazard ratio = 0.65). Objective response rate was significantly higher in the 175/75-mg group (22%) compared with the investigator's choice group (2%; P = .0019). Median overall survival for the temsirolimus 175/75-mg group and the investigator's choice group was 12.8 months and 9.7 months, respectively (P = .3519). The most frequent grade 3 or 4 adverse events in the temsirolimus groups were thrombocytopenia, anemia, neutropenia, and asthenia.

Conclusion Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL.

Supported by research funding from Wyeth Research, Collegeville, PA.

Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information can be found for the following: NCT00117598 [ClinicalTrials.gov] .

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Dreyling, W. Hiddemann, and for The European MCL Network Current treatment standards and emerging strategies in mantle cell lymphoma Hematology, January 1, 2009; 2009(1): 542 - 551. [Abstract] [Full Text] [PDF]